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Apoptosis research has been signiﬁcantly aided by the generation of antibodies against caspase-cleaved peptide neo-epitopes.
However, most of these antibodies recognize the N-terminal fragment and are speciﬁc for the protein in question. The aim of this
project was to create antibodies, which could identify caspase-cleaved proteins without a priori knowledge of the cleavage sites
oreventheproteinsthemselves.Wehypothesizedthatmanycaspase-cleavageproductsmighthaveacommonantigenicshape,
given that they must all ﬁt into the same active site of caspases. Rabbits were immunized with the eight most prevalent exposed
C-terminal tetrapeptide sequences following caspase cleavage. After puriﬁcation of the antibodies we demonstrated (1) their
speciﬁcity for exposed C-terminal (but not internal) peptides, (2) their ability to detect known caspase-cleaved proteins from
apoptotic cell lysates or supernatants from apoptotic cell culture and (3) their ability to detect a caspase-cleaved protein whose
tetrapeptidesequencediffersfromtheeighttetrapeptidesusedtogeneratetheantibodies.Theseantibodieshavethepotentialto
identify novel neo-epitopes produced by caspase cleavage and so can be used to identify pathway-speciﬁc caspase cleavage
events in a speciﬁc cell type. Additionally this methodology may be applied to generate antibodies against products of other
proteases, which have a well-deﬁned and non-promiscuous cleavage activity.
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Clinically translatable biomarkers of apoptosis would be
beneﬁcial in multiple disease areas, not the least of which is
cancer therapeutics. Many chemotherapeutics or biologics
ultimately induce apoptosis as their mode of action.
1,2 Thus,
the ability to monitor this increased apoptosis in patients
would enable an earlier determination of the success (or
failure) of a particular treatment. Likewise, from a drug
development perspective, earlier readouts of efﬁcacy will
improve costs and enable more nimble decision making.
3,4
There are several desired characteristics of an apoptotic
biomarker, especially for those with clinical translatability.
5
The constraint of non-invasiveness is a high bar over which
many biomarkers do not pass; tissues or organs that may be
obtainedinpreclinicalrodentmodelsofdiseasearesimplynot
accessible in patients in the clinic. This immediately narrows
down the possibilities for biomarkers into two realms: imaging
modalitiesorthosemeasurablefromeasy-to-collectbiological
specimens such as blood, urine, saliva, skin or hair. Another
concern is the stability of the analyte; the utility of a biomarker
is severely hampered if it is so short lived that special
measures must be employed for collection: it must be robust
enough to be performed by multiple users, as in a multi-center
study. A low background level of signal is another highly
desirable characteristic of biomarkers. Although some cas-
pase activity occurs in healthy organisms, the overall levels of
apoptosis in a healthy organism compared with the levels
induced by chemotherapy should be far above this back-
ground, leading to a satisfactory window of signal to noise.
Lastly,theverynatureofapoptosisaffordsitanadvantagenot
conferred to all biomarkers: a level of ‘universality’; in that the
core mechanism of apoptosis is largely cell-type independent.
This allows an apoptotic biomarker to have utility in a wide
range of disease types.
Caspase-cleavage products (CCPs) embody many of the
characteristics of a desired biomarker: increases in apoptosis
should cause elevations in caspase activity leading to
increased levels of CCPs; moreover if a CCP is serum- or
urine-stable it could be clinically translatable. An advantage of
detecting CCPs as a biomarker of apoptosis is speciﬁcity:
caspase cleavage of a protein creates a neo-epitope that
would primarily be present only under apoptotic conditions,
as executioner caspases generally are inactive under
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epitope antibodies (NEAs) can reasonably be assumed to
have only been formed during apoptosis and thus the levels of
suchCCPswouldcorrelatewiththeamountofapoptosis.One
such example of a CCP that is currently being utilized as a
biomarker of apoptosis is caspase-cleaved cytokeratin 18,
marketed as the Apoptosense ELISA from Peviva (Bromma,
Sweden) (see, for example, Brandt et al.
6). The aim of the
present study was to develop antibodies that could identify
CCPs without a priori knowledge of the cleavage sites or even
the proteins themselves. We describe the successful devel-
opment and validation of such antibodies.
Results
Immunization strategy. We hypothesized that many
CCPs might have a common antigenic shape, given that
they must all ﬁt into the same active site of execution-phase
caspases. To obtain the broadest coverage of neo-epitope
sites, we utilized an immunization scheme wherein rabbits
were injected with a cocktail of peptides containing the
eight most prevalent c-terminally exposed (after caspase
cleavage) tetrapeptide sequences, collectively called ‘DXXD’
(Figure 1a). Each of the eight peptides was coupled to two
different linker sequences (designated Scramble 1 and
Scramble 2), chosen to closely resemble native rabbit
peptides in order to minimize generation of antibodies to
these irrelevant parts of the immunogen. The cohort of
rabbits immunized with the mixture of eight Scramble 1 pep-
tides were boosted once with the Scramble 2 peptides, and
vise versa, such that the only commonality between immu-
nization and boost was the c-terminal DXXD sequences
(Figure 1b).
Puriﬁed antibodies are speciﬁc to the antigen
peptides. The antibody puriﬁcation strategy, outlined in
Figure 2a, employed both conventional and afﬁnity
chromatography. Following ammonium sulfate precipitation
of serum and DEAE ion-exchange column, the ﬂow-through
from the DEAE column was applied to the sulfolink afﬁnity
resin conjugated with the eight peptides (Scramble 3-DXXD).
Each of these eight peptides contains 12 amino acids,
comprising a ‘DXXD’ tetrapeptide used for the immunization,
and an octapeptide (Scramble 3) never seen by the host
animals. Thus the antibodies puriﬁed would be those speciﬁc
to the caspase substrate tetrapeptides, while the antibodies
recognizing linkers Scramble 1 or 2, or the carrier protein
OMPC, would not bind to the resin. The puriﬁcation progress
of the antibodies was visualized with SDS-PAGE and
western blot (Figure 2b). To verify that the puriﬁed
antibodies speciﬁcally recognized ‘DXXD’, direct ELISAs
were performed. As shown in Figure 2c, the puriﬁed
antibodies had high binding afﬁnity to all the eight
Scramble 3-DXXD peptides. Much lower binding afﬁnity
was observed when tested with similar peptides ending with
‘DXXDZZ’ (in this study ZZ represents two random amino
acids except C, D, E and M), indicating that these antibodies
speciﬁcally recognize the ‘DXXD’ at the end rather than in the
middle of the peptides. In other words, these antibodies are
potentially selective for cleaved caspase substrates but will
not recognize DXXD motifs in the intact (uncleaved) protein.
Additionally, it was conﬁrmed by ELISA that the puriﬁed
antibodies showed little or no binding to the sequences found
in Scramble 1 or 2, or OMPC (Figure 2d).
Puriﬁed antibodies speciﬁcally recognize cleaved
caspase substrates with a pattern of ‘DXXD’. Next, we
tested whether the puriﬁed antibodies were capable of
binding cleaved caspase substrates generated in apoptotic
cells. HCT116, a human colorectal carcinoma cell line, was
treated with a combination of 5-ﬂuorouracil (5-FU) and tumor
necrosis-related apoptosis-inducing ligand (TRAIL) to induce
apoptosis. The induction of apoptosis was conﬁrmed by
examining the positive annexin A5 binding of externalized
phosphatidylserine (PS), a hallmark of apoptosis (data not
shown). Cell lysates prepared from apoptotic HCT116 cells
were immune-precipitated with the puriﬁed antibodies,
applied to SDS-PAGE gels and western blotted for the
detection of cleaved caspase substrates. Caspase 6 and
Poly (ADP-ribose) polymerase (PARP) are two well-known
caspase substrates, whose caspase cleavage sites are
DVVD and DEVD, respectively. These two caspase
Figure 1 Strategy of immunization. (a) In all, 262 caspase-cleavage sites were analyzed to determine the most prevalent C-terminally exposed (after caspase cleavage)
tetrapeptidesequences.Basedonthisanalysis,thetopeightwerechosen.Thetetrapeptideswerejoinedtotwodifferenteightamino-acids‘linker’sequences(Scramble1and
Scramble 2), chosen to closely resemble native rabbit peptides in order to minimize generation of antibodies to these irrelevant parts of the peptide.( b) The cohort of rabbits
immunized with the mixture of eight Scramble 1 peptides were boosted once with the Scramble 2 peptides, and vise versa, such that the only commonality between
immunization and boost was the C-terminal DXXD sequences. Scramble 3 was utilized during puriﬁcation to decrease the isolation of irrelevant antibodies to the other linker
sequences
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Cell Death and Diseasesubstrate sequences were included in the eight tetrapeptides
used in the immunization. When the western blot was probed
with commercially available antibodies which recognize both
uncleaved and cleaved forms of caspase 6 (Figure 3a) or
PARP (Figure 3b), only the cleaved substrates were detected
in the pull-down fraction, demonstrating that our puriﬁed
antibodies speciﬁcally recognize cleaved caspase 6 and
PARP. However, when the apoptosis was attenuated by
adding QVD-OPH, a pan-caspase inhibitor, to the 5FU/
TRAIL-treated HCT116 cells, no speciﬁc bands could be
detected in the co-immuno-precipitated gel (Figures 3a and b),
nor were any speciﬁc bands detected in the rabbit IgG
immuno-precipitated cell lysate. These results further conﬁrm
that the puriﬁed antibodies are neo-epitope antibodies
(NEAs): they speciﬁcally recognize epitopes exposed
or generated during apoptosis and can be used to
immunoprecipitate such proteins. It should be noted that
the rabbit IgG bands were detected by the secondary anti-
rabbit antibodies on the blots given that the NEAs and the
detection antibodies (i.e. anti-PARP and anti-caspase 6)
were raised in the same species (rabbit). To avoid
precipitation, the samples were not boiled before loading
onto the gels. Therefore IgG oligmers were seen on the blots.
Cytokeratin 18 (CK-18) is another well-known caspase
substrate. During apoptosis, CK-18 is cleaved sequentially by
caspase 3 and caspase 6. A monoclonal antibody (M30)
developed by Peviva can speciﬁcally detect the caspase-
3-cleaved form of CK-18. The sequence of this cleavage site
is DALD, which was not one of eight tetrapeptides for
immunization. Nonetheless, it conforms to the same ‘DXXD’
pattern and should have a similar three-dimensional structure
as other ‘DXXD’ tetrapeptides. If the speciﬁcity of the puriﬁed
NEAs was based solely on the peptide sequence, no cleaved
caspase substrates whose cleavage sites are different from
the eight tetrapeptides should be precipitated by the anti-
bodies. However, if the speciﬁcity of the puriﬁed antibodies is
based on the structure or shape of the peptides, substrates
with any ‘DXXD’ pattern may be recognized by the NEAs.
To test whether the puriﬁed NEAs can recognize cleaved
CK-18, the apoptotic HCT116 cell lysates were immuno-
precipitated with our NEAs and probed with M30. Intriguingly,
the cleaved CK-18 was pulled down by the puriﬁed antibodies
(Figure 3c). This was further conﬁrmed by the in vitro pull-
down assay using recombinant caspase 3 and CK-18
proteins. In this series of experiments, recombinant CK-18
was incubated with recombinant caspase 3 in the presence or
absence of QVD-OPH, followed by the precipitation with the
puriﬁed NEAs and subsequent detection with M30. As shown
in Figure 3d, cleaved CK-18 was only captured by the puriﬁed
NEAs in the absence of QVD-OPH, indicating that the
speciﬁcity of the NEAs is based on the peptide structure of
caspase-cleaved ‘ends’ of proteins. Moreover, the puriﬁed
antibodies failed to pull down other cleaved caspase
substrates, such as caspase 7 or lamin A, whose cleavage
sites do not have Ds at P4 position (data not shown). To
further conﬁrm that the speciﬁcity of the puriﬁed NEAs is
structure-based, we coated the ELISA plates with peptides
terminating with amino-acid sequences DXXD, XXXD or
XXXX, then probed the plates with the puriﬁed NEAs to
measure the binding afﬁnity. None of the peptides tested had
the same DXXD sequences as the eight used for immuniza-
tion. Nonetheless, as expected, the puriﬁed antibodies bound
to peptide sequences ending in DXXD with high afﬁnity, but
little or no binding was observed to those not having
Figure 2 Puriﬁcation of antibodies. (a) Puriﬁcation scheme. The serum was fractionated with 50% ammonium sulfate and subsequent DEAE column as described in
‘Materials and Methods’. The ﬂow-through from theDEAE column was further puriﬁed with eight peptides(Scramble3-DXXD) conjugatedto sulfolink afﬁnity resin.The eluate
wascollectedandthetiterofantibodieswastestedbyELISA.(b)SDS-PAGEandwesternblotshowedthepuriﬁcationprogressoftheantibodies.(c)ELISAshowedthetiterof
antibodies puriﬁed from the serum of rabbit 2 against eight speciﬁc peptides (open circles). Scramble 1-DXXDZZ peptides were used as negative control to show the titer of
antibodiesagainstuncleavedsubstratesites(ﬁlledcircles).(d)ThehighO.D.valuesofScramble3-DEVD-coatedwellscomparedwithScramble1-,Scramble2-,Scramble3-,
and OMPC-coated wells are an example of the speciﬁcity of the puriﬁed antibodies, in all six rabbits tested
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at both positions seem to be critical for the binding of the
antibodies, as the peptides ending with XXXD did not show
binding afﬁnity to the puriﬁed antibodies.
In order to test the ability of the puriﬁed NEAs to identify
multiple caspase substrates, we performed an immuno-
precipitation experiment as follows: lysates from healthy or
apoptotic HCT-116 cells (±QVD-OPH) were incubated with
NEA. Captured proteins were then run on SDS-PAGE gels
and the proteins were identiﬁed by mass spectrometric
analysis of each lane from the gel. The arrows in Figure 4
indicate (as yet unidentiﬁed) proteins present more abun-
dantly in the lysates from apoptotic cells (middle lane) than in
lysates from healthy or QVD-OPH-treated cells. We identiﬁed
at least four proteins, which were present in the lysates from
apoptotic cells, but not in the healthy or QVD-OPH-treated
lysates. Signiﬁcantly, CK-18 was one of these proteins,
conﬁrming the results obtained in Figure 3c. In addition,
DNA protein kinase (catalytic subunit) was also present
exclusively in immunoprecipitations from the apoptotic HCT-
116 cell lysates; this protein has been previously identiﬁed as
a caspase 3 substrate.
7 Elongation factor 1-B (EF1-B) was
similarly identiﬁed by NEA precipitation in apoptotic lysates.
The caspase substrate sequence DETD is present at amino
acid 151–155 of human EF1-B. Moreover, Zebraﬁsh EF1-B is
cleaved by the zebraﬁsh ortholog to caspase 3.
8 Finally, the
60S ribosomal protein L21 was identiﬁed only in the
immunoprecipitation of lysates from apoptotic cells. Although
there are no literature reports of this protein being a caspase
substrate, the amino-acid sequence contains a putative
substrate-recognition sequence (DIVD) at positions 38–41.
These data indicate that both known and (potentially) novel
caspase substrates can be identiﬁed using the NEA reagents.
The puriﬁed neo-epitope antibodies can immuno-
precipitate secreted caspase-cleavage products. As a
pre-requisite step for validation as plasma biomarkers for
apoptosis, it was important to determine whether puriﬁed
NEAs could bind caspase-cleavage products, such as
cleaved CK-18, secreted into the medium from cultures of
apoptotic cells. To this end, culture medium from apoptotic
HCT116 cells was immuno-precipitated with puriﬁed NEAs,
Figure 3 Puriﬁed antibodies speciﬁcally recognize cleaved caspase substrates with a pattern of ‘DXXD’. Apoptosis was induced by 5-FU and TRAIL in HCT116 cellsa s
described in ‘Materials and Methods’. QVD-OPH was added to block caspase activities as indicated. Cell lysate from 10
7 cells was immuno-precipitated with 20mg of puriﬁed
antibodies,thendetectedwithantibodiesagainstPARP(a),caspase6(b)orcleavedCK-18(c),separately.Thepuriﬁedantibodiesspeciﬁcallyrecognizenotonlythecleaved
PARP (DEVD) and caspase 6 (DVVD) whose caspase cleavage sites are one of the eight peptides used for immunization, but also the cleaved CK-18 (DALD), whose
tetrapeptide cleavage site was not one of the eight peptides, but has aspartic acid at the P1 and P4 position. However, the puriﬁed antibodies do not recognize the cleaved
caspase 7 (IQAD) or lamin A (VEID) whose tetrapeptide cleavage sites has a ‘D’ at P1 but not P4 position (data not shown). Rabbit IgGs in the immune precipitate were
detected as artifacts in western blots (as labeled) by the secondary antirabbit antibodies. This was due to the fact that both the NEAs and the detection antibodies
(i.e. anti-PARP and anti-caspase 6) were raised in the same species (rabbit). Furthermore, to avoid precipitation, samples were not boiled before loading onto gels, therefore
IgG oligmers were seen on the blots. (d) Puriﬁed antibodies speciﬁcally pull down cleaved recombinant CK-18. A total of 10mg of recombinant CK-18 was cleaved with
caspase3invitro.QVD-OPHwasaddedtoblockcaspaseactivitiesasindicated.Thereactionwasprecipitatedwithpuriﬁedantibodiesandthendetectedwithantibodyagainst
cleaved CK-18. (e) Peptides with a ‘D’ at P1, or P1 and P4 (IETD, LQTD, SECD, DCRD, FRHD and FAED) were coated on the ELISA plates, and probed with puriﬁed
antibodies. Scramble 3-DETD and Scramble 3 peptides were coated as positive and negative control, respectively. The antibodies only recognize the peptides with aspartic
acids at both the P1 and P4 position (i.e. DCRD and DETD), but not the ones with a ‘D’ only at P1 position
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antibody recognizing cleaved PARP. As shown in Figure 5,
both cleavage products were precipitated from apoptotic cell
culture supernatants and were detectable by their respective
antibodies. The fact that more than one caspase-cleavage
product could be precipitated from the same medium
preparation by the same NEA preparation, demonstrates
the potential of using puriﬁed NEAs to identify novel neo-
epitopes generated during apoptosis, providing additional
targets for validation as circulating biomarkers of tumor
response.
Discussion
Increased caspaseactivityis oneof the hallmarksof apoptotic
cell death. Thus, products cleaved by this class of proteases
may serveas effective biomarkers of apoptosis. One example
of such a protein is caspase-cleaved cytokeratin 18 (CK-18).
Both cleaved and uncleaved CK-18 are serum stable; indeed,
commerciallyavailablekits(ApoptosenseM30andM65)have
been used to measure CK-18 processing as a biomarker of
apoptosisornecrosisina varietyofdifferentsettingsincluding
human clinical trials.
9 Inthis regard, Dix et al.
10 reported many
of the caspase-cleaved products (CCPs) appear to be stable
(relative to the half life of the uncleaved ‘parent’ protein),
making a strong case for the identiﬁcation of other CCPs as
potential clinically relevant biomarkers of apoptosis. Such
biomarkers could be measured in accessible tissue compart-
ments such as plasma, urine and cerebrospinal ﬂuid.
The aim of the present study was to develop antibody-
based tools to enable the discovery of novel CCPs. One
advantage of an antibody-based (rather than a proteomics-
based) approach to the identiﬁcation of new apoptosis
biomarkers,
3 is that the discovery tool (antibody) may itself
be further optimized for biomarker detection/validation. Anti-
bodies produced through immunization with peptide cocktails
have been applied extensively for the generation of reagents
speciﬁc for distinct epitopes of the same protein. We applied a
similar technique for the ﬁrst time to create antibodies that
would recognize multiple proteins whose commonality was a
caspase-cleaved end region. In order to create such neo-
epitope antibodies (NEAs), we analyzed the CASBAH
database and rank ordered the caspase-cleavage sites within
the database. The eight most represented cleavage sites
were chosen to use in our immunization scheme. All eight
siteshadanasparticacidatpositionsP1andP4,leadingusto
collectively call these eight sequences ‘DXXD’. In fact, DXXD
Figure 4 Puriﬁed antibodies can immunoprecipitate different proteins from
apoptotic cell lysates compared with lysates of healthy or caspase-inhibited cells.
Immunoprecipitated cell lysates from cells as in Figure 3 were also resolved by
SDS-PAGE and protein bands were visualized by Coomassie blue staining. Clear
differences were observed; arrows indicate for example, at least ﬁve (as yet
unidentiﬁed)bandsdistinctlymorevisibleintheapoptoticcelllysatescomparedwith
lysates from healthy or caspase-inhibited cells. Sections of the gel were cut and
subjected to trypsin digestion and mass spectrometry identiﬁcation. Three known
caspase substrates (CK-18, DNA PK and EF1-B) and a novel one (60S ribosomal
protein L21) were identiﬁed in apoptotic cell lysates
Figure5 PuriﬁedantibodiesspeciﬁcallyrecognizecleavedPARPandCK-18inapoptoticmedia.Apoptosiswasinducedby5-FUandTRAILinHCT116cellsasdescribed
in ‘Materials and Methods’. QVD-OPH was added to block caspase activities as indicated. Cell media from 10
7 cells was concentrated and immuno-precipitated with 20mgo f
puriﬁed antibodies, then detected with antibodies against PARP (a), or cleaved CK-18 (b), separately. The puriﬁed antibodies speciﬁcally recognize the cleaved PARP and
CK-18 released to the media. The rabbit IgG bands from the antibodies were labeled as well
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33% of the 724 caspase-cleavage sites recently collated
(manuscriptinpreparation).Wehypothesizedthatthepuriﬁed
NEAs would recognize the caspase-cleaved motif based on
its ‘shape’ (i.e. based on tertiary structure) rather than the
sequence. The fact that the antibodies bind to all eight
peptides with similar afﬁnity regardless of whether the
antibodies were afﬁnity puriﬁed from any of a single-peptide-
conjugated column or from eight-peptide-conjugated column,
further conﬁrms this hypothesis (data not shown).
In addition to immunizing rabbits with a pool of peptides
rather than a single amino-acid sequence, the antigenic boost
injections contained an alternate set of eight peptides that
differed only in their linker region (i.e. remaining constant in
their terminal, ‘caspase cleaved’ sites). This increased the
chances of antibody production to the desired DXXD region of
the immunogen. Success of this crossover-boosting strategy
was validated; even before puriﬁcation, the titers of the NEA
serum to the two linker regions (Scramble 1 or Scramble 2)
were considerably lower than to the DXXD region.
As a proof of concept for their utility as broad-speciﬁcity
caspase-cleaved substrate detectors, the NEAs were used to
precipitate proteins from lysates of cells induced to undergo
apoptosis in the presence or absence of caspase inhibitors.
Using this approach, both known (PARP, caspase 6, CK-18,
DNA PK and EF1-B) and novel (60S ribosomal protein L21)
caspase substrates were identiﬁed in apoptotic cell lysates.
Importantly, the non-cleaved forms of PARP, caspase 6 and
CK-18 (present in healthy cells) were not detected by the
same antisera. It is noteworthy that although the cleavage site
within CK-18 maintains the DXXD motif, DALD, this peptide
was not one of the eight sequences used in immunization,
further supporting our hypothesis that the NEAs can detect
many DXXD motifs based on their conformation and not their
sequence.
Moreover, in additional ELISA-based validation experi-
ments, the second most highly recognized peptide had the
DXXDmotif,DCRD(thecaspase-cleavagesiteofNFkB
11),but
againwasnotone ofthe eightoriginalpeptide sequences used
for immunization. Conversely, the NEAs failed to immunopre-
cipitatecleavedcaspase7orLaminA(datanotshown),bothof
whichhavecaspase-cleavagesitesconsistingofXXXD;thatis,
where the P4 amino acid was not aspartic acid. A terminal
DXXD sequence is much more likely to represent a caspase
cleavage event compared with an internal DXXD sequence.
Thus, to fulﬁll its utility as a tool to ﬁnd caspase-cleaved
proteins, it is imperative that the NEAs recognize DXXD only in
the context of the end of a peptide, as would be found after
caspase cleavage.Thiswas the case,asthe titersofthe NEAs
were generally much higher for the DXXD peptides compared
with peptides constructed to mimic an uncleaved (internal)
state, DXXDZZ (where the ZZ represents random amino-acid
pairs). Additionally, full-length caspase 6 or PARP are not
immunoprecipitated by the NEAs, further conﬁrming the utility
of the NEAs as a tool to detect caspase-cleaved proteins by
virtue of their newly exposed caspase-cleaved terminus. More
intriguing, the puriﬁed NEAs were able to recognize not only
cleaved CK-18 but also cleaved PARP peptides in media
conditionedbyapoptoticcells.Toourknowledge,thisistheﬁrst
time that cleaved PARP has been shown to be released from
apoptotic cells, suggesting a new clinical application: using
cleaved PARP as a plasma biomarker for the apoptotic
response of solid tumors.
There exist at least two previous examples of antibodies
that recognize caspase-cleaved ‘ends’ of more than one
protein, although this is by serendipity rather than design.
Ab127 was produced by immunizing with a KLH-conjugated
peptide corresponding to six amino acids of the PARP
cleavage site (KGDEVD).
12 Under apoptotic conditions, this
antibody recognized a protein of 47kD, rather than the
predicted B30 or B85kD fragments given upon caspase
cleavage of PARP. The second example is mentioned in the
same publication, though the authors were unaware of its
ability to recognize more than one caspase-cleavage epitope.
sc45, an antibody that is commercially available (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA) was ﬁrst reported
to detect c-Jun (amino acids 73–87 of rat c-Jun
13). The
terminal four amino acids of this epitope are NVTD. Later, it
was demonstrated that sc45 cross-reacted with other
proteins, following caspase 3 cleavage, at sites that did not
contain the c-Jun sequence.
14 Seryl-tRNA is one such
protein,
15 although the caspase-cleavage site of seryl-tRNA
is EVTD rather than NVTD. What is especially noteworthy
about this caspase-cleavage site is that the P1 aspartate is
the penultimate amino acid of seryl-tRNA. In other words,
caspasecleavageappears to liberate only asingle amino acid
(the C-terminal alanine). The NEAs generated in the present
study also fail to detect a DXXD that is only one amino acid
from the end of a peptide; when tested against the peptide
ending in DEVD, titers in excess of 1:50000 were observed
compared with a titer of only 1:3000 when the identical
peptide ending in DEVDG was tested. Caspase cleavage
events occurring so close to the C-terminal region of proteins
are undoubtedly under-represented in both CASBAH and
even in non-biased screens for caspaseactivity.
16 In contrast,
the NEAs outlined in this study, could potentially identify both
internal peptides and terminal/penultimate amino-acid clea-
vage events.
Mass spectrometric methods of detection, while sensitive
enough to detect amino-acid differences in mass or
sequence, suffer from the limited ability to capture such
events. In this regard, two previous studies have greatly
extended the known pool of caspase substrates. In the
ﬁrst, the Cravatt laboratory
10 developed a high-content
proteomic platform to proﬁle proteolytic events occurring
in biological systems termed PROTOMAP (for PROtein
TOpography and Migration Analysis Platform). Using this
approach, they identiﬁed more than 150 proteins not
previouslyknowntobecleavedduringJurkatT-cellapoptosis.
In the second study, Wells and co-workers
16 used an
engineered enzyme to selectively biotinylate free-protein
N termini for positive enrichment of corresponding N-terminal
peptides to study the proteolytic events of apoptosis. They
sequenced more than 290 substrates not predicted by in vitro
caspase-substrate speciﬁcity. However, neither of these
studies provides practical tools to follow up on the validation
of novel substrates as biomarkers of apoptosis. In contrast,
the utility of NEAs described in the present study will expand
the prospective pool of proteins that serve as biomarkers of
apoptosis.
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DEPD, DEAD, DSVD, DVVD and DEQD, hereafter collectively referred to as
‘DXXD’). Three different octapeptide linker sequences (Scramble 1, 2 and 3) were
chosen to closely resemble native rabbit peptidesin order to minimize generation of
antibodies to these irrelevant parts of the peptide. (Scramble 1 and 2 were used for
immunization, Scramble 3 was utilized during puriﬁcation to decrease the isolation
ofirrelevantantibodiestotheselinkersequences.)Allpeptidesweresynthesizedby
JPT Peptide Technologies (Acton, MA, USA) with an N-terminal cysteine followed
by a 6-aminohexanoic acid reside (ahx) in order to aid in the conjugation and
quantiﬁcation of conjugation, respectively.
18 Finally, the C-terminal aspartate was
synthesized as a free acid to more closely resemble the end of a caspase-cleaved
protein. The peptides synthesized are shown in Figure 1a.
The outer membrane protein complex (OMPC) of Neisseria meningitidis is an
excellent carrier protein
19 to which peptides may be conjugated in order to increase
immunogenicity.
20 All 16 peptides (eight C-ahx-Scramble 1-DXXD and eight C-ahx-
Scramble 2-DXXD) were individually conjugated to OMPC via thiol-based
conjugation chemistry essentially as previously described,
21 except that the
duration of maleimide activation of OMPC was 4h rather than 1h, and the peptide
thiol/maleimide molar ratio was 1.5 rather than 3. Protein concentrations of the 16
peptide-OMPC conjugates were determined by the Lowry assay. Eight Scramble
1-DXXD (1.25mg each) or the eight Scramble 2-DXXD conjugates (1.25mg each)
were combined to create antigen set A (the pool of all eight OMPC-Scramble
1-DXXD conjugates) and antigen set B (combination of 1.25mg of each of the
OMPC-Scramble 2-DXXD conjugates), respectively.
Antibody production: Polyclonal antibodies were produced by SDIX
(Newark, DE, USA) according to their established 99-day protocol, and in
facilities that are registered and accredited with AAALAC, USDA, PHS/NIH/OLAW,
DEA and APHIS. Rabbits were pre-bled, and the six whose plasma showed the
least signal when immunoblotted with antirabbit secondary abs were chosen. A
group of three rabbits was initially immunized and boosted (on days 13, 26 and 41)
withantigensetA,whileanothergroupofthreerabbitswasimmunizedandboosted
on the same days with antigen set B. On day 70, the ﬁnal boost was switched such
that the rabbits immunized with antigen set A were given their ﬁnal boost with
antigensetBandviseversa,suchthattheonlycommonalitybetweenimmunization
and ﬁnal boost was the C-terminal DXXD sequences. Serum containing polyclonal
antibodies from all six rabbits was collected at day 99.
Column conjugation and antibody puriﬁcation: SulfoLink
Immobilization kit (Pierce Biotechnology, Rockford, IL, USA) was used to
conjugate the peptide and purify the antibodies. The manufacturer’s instruction
was followed. In brief, every 2mg of Scramble 3-DXXD peptides (either single
peptideorthemixof0.25mgofeachoftheeightpeptides)weredissolvedin2mlof
coupling buffer (50mM Tris, 5mM EDTA-Na, pH 8.5), reduced with 25mM TCEP
and incubated for 30min. The sulfhydryl-containing peptides were then coupled to
2-ml Sulfolink columns by mixing with the SulfoLink resin for 15min followed by a
30-min incubation. Non-speciﬁc binding sites were blocked with 50mM cysteine by
mixing for 15min and subsequent incubation for 30min. The columns were then
equilibrated with binding/wash buffer (TBS) before the afﬁnity puriﬁcation step. All
steps were performed at room temperature.
Theantibody puriﬁcation schemeis summarized in Figure 2a. Thefractions from
each step were monitored by SDS-PAGE and western blot to conﬁrm the
puriﬁcationofantibodies;thespeciﬁcityoftheantibodieswasveriﬁedbyELISA.The
serum from each of the six rabbits was ﬁrst fractionated by ammonium sulfate
precipitation. The serum was centrifuged at 10000 g for 30min at 41C to remove
any large aggregates. The supernatant was collected, and an equal volume of
saturated ammonium sulfate solution (Pierce Biotechnology) was added to the
supernatant drop by drop on ice with gentle stirring. The mixed solution was rotated
for at least 3h (up to over night) at 41C followed by centrifugation at 10000 g for
30min at 41C. The pellet was resuspended with a minimal volume of 20mM Tris-
HCl (pH 7.5), and dialyzed against 20mM Tris-HClþ50mM NaCl (pH 7.5) before
being applied to a HiPrep 16/10 DEAE_FF ion-exchange column (GE Healthcare
Biosciences, Piscataway, NJ, USA). A 200ml of linear gradient from 50mM to
500mM of NaCl was applied to the column to elute the bound protein. The ﬂow-
through was pooled and applied to the Scramble 3-DXXD peptides-conjugated
SulfoLink column. The column was incubated at room temperature with rocking for
30–60min to allow binding to occur. Following the wash step, the antibodies that
speciﬁcally recognize the eight DXXD peptides were eluted with 0.1M glycine (pH
3.0), and neutralized with 1M Tris (pH 8.5).
ELISAassays: Titersofpre-bleed,post-bleed seraandﬁnal-puriﬁedaliquotsof
antibodies were determined via colorimetric ELISA. Plates (96-well) were coated
with 10mg/ml of peptide for a minimum of 2h (up to overnight at 41C), then blocked
(without removing coating solution) with TBS-T/BSA (150mM NaCl, 50mM Tris,
0.05% Tween-20 and 1% BSA) for an additional 2h. The wells were rinsed three
times with TBS-T, aspirated and 95ml of serially diluted sera/antibodies (1:10
3 up
to 1:10
6) were added and allowed to incubate at room temperature for 1–2h on an
orbital shaker. The wells were again rinsed three times with TBS-T, aspirated and
60ml of1:5000donkeyanti-rabbit-HRPantibody(GEHealthcareBiosciences)was
addedandincubatedfor1–2honanorbitalshaker.Wellswereaspiratedandrinsed
three times with TBS-T after which 100ml of TMB substrate (Pierce Biotechnology)
was added and incubated in the dark until appropriate coloration was observed, at
which point 50mlo f1MH 2SO4 was added to stop the reaction and the absorbance
(450nm wavelength) was measured on a spectramax M2e spectrophotometer
(Molecular Devices, Sunnyvale, CA, USA).
Apoptosis induction, immunoprecipitation and immuno-
blotting: The conditions and time points of apoptosis induction for HCT-116
cells (ATCC) have been optimized to give maximal induction. Brieﬂy, an B80%
conﬂuent 10-cm plate of cells was incubated with 400mM 5-Fluorouracil (5-FU, in
DMSO, Sigma-Aldrich, St. Louis, MO, USA) for 17h, then 200ng/ml recombinant
TRAIL (MP Biomedical, Solon, OH, USA) was added to the media and cells were
incubated for an additional 3h. This dosing paradigm reproducibly induced
apoptosis (450% annexin A5 positive) with minimal amounts of membrane
permeability as measured by propidium iodide uptake. That this apoptotic induction
wascaspase-dependent,wasconﬁrmedinthatconcomitantadditionofthecaspase
inhibitor QVD-OPH (MP Biomedical) reduced peak Annexin A5 positivity by 50% or
more (data not shown).
Apoptotic cells (10
7) (or non-induced and 5-FU/TRAIL/QVD-OPH treated)
were harvested and lysed with RIPA lysis buffer (Pierce Biotechnology) containing
proteaseinhibitorcocktail(PierceBiotechnology)at41C.Celllysateswerecollected
with QIAshredder column (Qiagen, Valencia, CA, USA) at 10000 g for 2min at
41C, then the protein concentration was determined with a BCA Protein Assay kit
(Pierce Technology). About 500mg of cell lysates were pre-cleared by mixing with
50ml of GammaBind Plus Sepharose (GE Healthcare Biosciences) for 1h to
overnight at 41C to decrease the background. Pre-cleared cell lysates were
incubated with 10mg of puriﬁed neo-epitope antibodies (NEAs) for 1h at 41C
followedbymixingwith50mlofGammaBindPlusSepharoseforanother1hat41C.
After the incubation, the resin was washed with RIPA buffer, and antibody-bound
proteins were eluted with 2 SDS buffer (BostonBioproducts,Ashland,MA, USA).
Rabbit IgG (Invitrogen, Carlsbad, CA, USA) was mixed with cell lysates and
GammaBind Plus Sepharose in parallel as a negative control.
The following primary antibodies were used in immunoblotting: anti-PARP (Cell
Signaling Technologies, Danvers, MA, USA), anti-Caspase 6 (Cell Signaling
Technologies), M30 (Peviva through Diapharma, West Chester, OH, USA).
Immunoprecipitated cell lysates were loaded onto Bis-Tris gradient gels (Invitrogen)
and run according to the manufacturer’s directions. Gels were transferred to
nitrocellulose using a wet-transfer protocol and blocked for 1h in Odyssey blocking
buffer (LI-COR Biosciences, Lincoln, NE, USA). Blots were incubated overnight at
41C with primary antibodies in blocking buffer supplemented with 0.1% Tween-20
(Sigma-Aldrich). Blots were rinsed with TBS-T, and IR-dye-labeled secondary
antibodies (LI-COR) were applied at 1:15000 in blocking buffer supplemented with
0.1% Tween-20 and 0.01% SDS for 1h. All blots were imaged using the Odyssey
infrared scanner (LI-COR). To avoid precipitation, the samples were not boiled before
loading onto the gels. Therefore IgG oligmers were seen on the gels.
Immunoprecipitated cell lysates from apoptotic cells (or non-induced and 5-FU/
TRAIL/QVD-OPH treated) were also resolved by SDS-PAGE and protein bands
were visualized by Coomassie blue staining. The protein bands were cut and
subjected to trypsin digestion and mass spectrometry identiﬁcation.
Recombinantcaspase3cleavage: Theinvitrocaspase3cleavageassay
was performed in buffer composed of 50mM HEPES (pH 7.3), 100mM NaCl, 5%
(w/v) glycerol, 0.5mM EDTA, 0.05% (w/v) CHAPs and 5mM dithiothreitol.
RecombinantCK-18(10mg)(MPBiomedical)wasmixedwith0.2mgofrecombinant
caspase 3 (Sigma-Aldrich) in the presence or absence of QVD-OPH
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